Treating pain can be tricky for practitioners and patients with a heightened awareness of the dangers surrounding the opioid addiction epidemic in Massachusetts. One local doctor is offering an alternative: cold laser therapy, with the promise of pain relief without the pills.
Last fall, Christine Hart was facing surgery for a hip injury and osteoarthritis.
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta known as Cdx2 cells can regenerate healthy heart cells after heart attacks in animal models. The findings, published in the May 20 issue of Proceedings of the National Academy of Sciences (PNAS), may represent a novel treatment for regenerating the heart and other organs.
“Cdx2 cells have historically been thought to only generate the placenta in early embryonic development, but never before were shown to have the ability to regenerate other organs, which is why this is so exciting. These findings may also pave the way to regenerative therapy of other organs besides the heart,” said principal investigator Hina Chaudhry, MD, Director of Cardiovascular Regenerative Medicine at the Icahn School of Medicine at Mount Sinai. “They almost seem like a super-charged population of stem cells, in that they can target the site of an injury and travel directly to the injury through the circulatory system and are able to avoid rejection by the host immune system.”
This team of Mount Sinai researchers had previously discovered that a mixed population of mouse placental stem cells can help the hearts of pregnant female mice recover after an injury that could otherwise lead to heart failure. In that study, they showed that the placental stem cells migrated to the mother’s heart and directly to the site of the heart injury. The stem cells then programmed themselves as beating heart cells to help the repair process.
Posted in aging, bioengineering, biotech/medical, business, defense, DNA, health, life extension, military, science
May is almost over, so it’s time to check in with the Ending Age-Released Diseases conference and see how things are developing with the event.
If you’re unfamiliar with us, we’re hosting our second annual conference at the Cooper Union in New York City on July 11-12th this year. It will feature some of the leading names in both aging research and biotech business and investment coming together to share their knowledge and insights with the audience.
Aging research is on the cusp of some major breakthroughs in the battle against age-related diseases, and we invite you to join us for an action-packed event filled with exciting talks and discussion panels featuring some of the leaders of aging research and the biotech business.
DARPA has awarded funding to six organizations to support the Next-Generation Nonsurgical Neurotechnology (N) program, first announced in March 2018. Battelle Memorial Institute, Carnegie Mellon University, Johns Hopkins University Applied Physics Laboratory, Palo Alto Research Center (PARC), Rice University, and Teledyne Scientific are leading multidisciplinary teams to develop high-resolution, bidirectional brain-machine interfaces for use by able-bodied service members. These wearable interfaces could ultimately enable diverse national security applications such as control of active cyber defense systems and swarms of unmanned aerial vehicles, or teaming with computer systems to multitask during complex missions.
“DARPA is preparing for a future in which a combination of unmanned systems, artificial intelligence, and cyber operations may cause conflicts to play out on timelines that are too short for humans to effectively manage with current technology alone,” said Al Emondi, the N program manager. “By creating a more accessible brain-machine interface that doesn’t require surgery to use, DARPA could deliver tools that allow mission commanders to remain meaningfully involved in dynamic operations that unfold at rapid speed.”
Over the past 18 years, DARPA has demonstrated increasingly sophisticated neurotechnologies that rely on surgically implanted electrodes to interface with the central or peripheral nervous systems. The agency has demonstrated achievements such as neural control of prosthetic limbs and restoration of the sense of touch to the users of those limbs, relief of otherwise intractable neuropsychiatric illnesses such as depression, and improvement of memory formation and recall. Due to the inherent risks of surgery, these technologies have so far been limited to use by volunteers with clinical need.
A research team has developed a light beam device that could lead to faster internet, clearer images of space and more detailed medical imaging.
University of Queensland researcher and optical engineer Dr. Joel Carpenter worked with Nokia Bell Labs to build the device to tackle the challenge of splitting light into the shapes it is made up of, known as modes.
“Splitting a beam of light into colours is easy because nature gives you that one for free—think of rainbows or when light shines through glass at an angle,” Dr. Carpenter said.
JOHANNESBURG (AP) — The global health community gulped Thursday with the announcement that a case of Ebola had been confirmed in a city of more than 1 million in Congo, bringing the latest outbreak of the often deadly hemorrhagic fever out of remote rural areas. “Confirmation of urban #Ebola in #DRC is a game changer in this outbreak – the challenge just got much much tougher,” the World Health Organization’s emergencies chief, Dr. Peter Salama, said on Twitter. Here’s a look at the outbreak.
What is Ebola?
Ebola is a virus that without preventive measures can spread quickly between people and is fatal in up to 90 percent of cases. The symptoms include fever, vomiting, diarrhea, muscle pain and at times internal and external bleeding. Symptoms can start to occur between two and 21 days from infection, according to WHO.
